Drug Profile
GR 253035
Latest Information Update: 10 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease; Pain
Most Recent Events
- 20 Jul 1999 Profile reviewed
- 20 Jul 1999 Discontinued-I for Alzheimer's disease in USA (Unknown route)
- 20 Jul 1999 Discontinued-I for Pain in USA (Unknown route)